Equities

Delcath Systems Inc

Delcath Systems Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)7.35
  • Today's Change-0.43 / -5.53%
  • Shares traded304.58k
  • 1 Year change-4.68%
  • Beta0.6282
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

  • Revenue in USD (TTM)4.61m
  • Net income in USD-49.79m
  • Incorporated1988
  • Employees76.00
  • Location
    Delcath Systems Inc566 Queensbury AvenueQUEENSBURY 12804United StatesUSA
  • Phone+1 (518) 743-8892
  • Fax+1 (212) 489-2102
  • Websitehttps://delcath.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stereotaxis Inc27.10m-21.22m157.85m122.00--10.77--5.82-0.2575-0.25750.32880.24390.60121.456.14222,155.70-44.08-25.02-63.05-34.1255.1667.57-73.32-41.901.79--0.00---4.89-1.82-12.33--6.63--
CVRx Inc42.09m-52.01m159.38m200.00--2.41--3.79-2.48-2.482.013.070.36780.67815.64210,430.00-45.45---48.95--84.45---123.58--10.87-21.110.3064--74.89--0.5528------
InfuSystem Holdings Inc127.41m84.00k159.93m499.002,701.443.0613.011.260.00280.00285.912.461.2310.666.57255,330.700.08114.600.09555.6950.2756.430.06594.071.511.560.36410.0014.4413.384,744.44--6.01--
Akso Health Group - ADR2.20m-17.07m173.09m12.00------78.58-0.7466-0.24610.0963--0.11661.910.3202183,560.00-89.84-17.36-224.28-23.997.56---770.59-256.641.36-24.020.6531--119.69-34.25-221.68------
Inogen Inc321.52m-96.68m202.76m834.00--1.06--0.6306-4.15-4.1513.818.150.9176.036.83385,519.20-27.57-8.23-34.28-9.5340.5444.54-30.07-10.312.36--0.00---16.32-2.49-22.30--26.34--
Neuropace Inc69.07m-31.51m203.97m171.00--14.20--2.95-1.18-1.182.590.49940.67351.626.63403,935.70-30.72---34.60--73.97---45.61--5.56-4.670.8019--43.72--30.00------
Delcath Systems Inc4.61m-49.79m204.23m76.00--12.79--44.33-2.65-2.650.23570.57470.13820.45454.5660,618.42-149.30-116.57-249.28-243.2170.5471.02-1,080.73-1,235.372.25-42.250.3348---24.05-9.53-30.60---5.26--
Semler Scientific Inc65.88m21.69m204.91m92.0010.442.589.183.112.782.788.4511.260.85515.138.51716,097.8028.1438.8331.1444.4189.4390.2232.9232.5812.11--0.00--20.2825.9843.6932.64-0.3821--
Outset Medical Inc125.08m-168.77m205.86m480.00--2.21--1.65-3.38-3.382.501.800.35291.823.53260,577.10-47.61-41.40-54.98-47.2924.615.71-134.93-159.055.32-32.130.6786--13.00130.43-6.04--14.27--
Butterfly Network Inc68.08m-121.92m217.03m225.00--1.06--3.19-0.5893-0.58930.3290.96850.20450.69544.97302,577.80-36.61---42.07--26.50---179.08--3.34--0.00---10.21--20.76------
Edap Tms SA (ADR)65.71m-19.79m217.06m307.00--3.77--3.30-0.5347-0.53471.781.550.63772.393.53214,046.10-19.21-6.62-26.95-9.2240.9143.23-30.12-9.592.00--0.0757--9.649.05-622.06--32.75--
Senseonics Holdings Inc23.30m-80.59m230.94m132.00--12.18--9.91-0.1354-0.13540.0390.10670.16352.516.51176,515.20-56.55-73.65-66.90-106.9712.93-40.41-345.89-649.863.70-11.130.4783--36.623.43-142.49---18.76--
Utah Medical Products, Inc.49.04m16.38m242.93m169.0015.271.9311.244.954.514.5113.5035.600.37272.0913.24290,201.2012.4412.6913.0213.1959.0561.5733.3930.5117.89--0.0037.05-3.933.640.98341.659.711.86
Orchestra Biomed Holdings Inc2.22m-51.64m249.45m56.00--4.36--112.57-1.47-1.470.0631.600.02031.0130.9939,571.43-47.18---52.58--92.06---2,330.46--7.33--0.00---21.88---37.91------
AngioDynamics, Inc.324.01m-192.37m249.94m815.00--1.15--0.7714-4.78-4.788.105.410.74682.666.46397,555.80-44.34-9.12-54.02-10.1750.1754.23-59.37-19.481.62--0.00--7.135.30-97.54--3.55--
Data as of May 28 2024. Currency figures normalised to Delcath Systems Inc's reporting currency: US Dollar USD

Institutional shareholders

35.76%Per cent of shares held by top holders
HolderShares% Held
Rosalind Advisors, Inc.as of 18 Apr 20242.65m12.02%
AIGH Capital Management LLCas of 31 Mar 20242.36m10.70%
BVF Partners LPas of 31 Mar 20241.20m5.45%
The Vanguard Group, Inc.as of 31 Mar 2024680.81k3.09%
CIBC World Markets, Inc.as of 31 Mar 2024260.28k1.18%
Geode Capital Management LLCas of 31 Mar 2024223.01k1.01%
Adar1 Capital Management LLCas of 31 Mar 2024218.97k0.99%
Hunting Hill Global Capital LLCas of 31 Mar 2024104.40k0.47%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 202494.79k0.43%
BlackRock Fund Advisorsas of 31 Mar 202488.98k0.40%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.